Osiris Therapeutics, Inc.
OSIRIS THERAPEUTICS, INC. (Form: 3, Received: 09/21/2017 15:54:45)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Keefer Jason

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/21/2017 

3. Issuer Name and Ticker or Trading Symbol

OSIRIS THERAPEUTICS, INC. [OSIR]

(Last)        (First)        (Middle)

7015 ALBERT EINSTEIN DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Interim President & CEO /

(Street)

COLUMBIA, MD 21046       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   2/17/2015   (1) 2/17/2025   Common Stock   15000   $16.24   D  
 
Incentive Stock Option (right to buy)   9/21/2016   (2) 9/21/2026   Common Stock   1000   $19.20   D  
 

Explanation of Responses:
(1)  3,750 shares underlying this option shall vest on each of February 17, 2015, February 17, 2016, February 17, 2017 and February 17, 2018, subject to Reporting Person's continued service through the applicable vesting date.
(2)  250 shares underlying this option shall vest on each of September 21, 2016, September 21, 2017, September 21, 2018 and September 21, 2019, subject to Reporting Person's continued service through the applicable vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Keefer Jason
7015 ALBERT EINSTEIN DRIVE
COLUMBIA, MD 21046


Interim President & CEO

Signatures
/s/ Jason Keefer 9/21/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.